Abera and Denmark-based collaborators Expres2ion Biotechnologies ApS and University of Copenhagen have received Eurostars funding for the project named OptiFemVac.
Aim of the project is to develop vaccines targeting female reproductive and infant health, enhanced by delivery platforms designed to produce and deliver efficacious vaccines more cost effectively. The platforms allow optimal display of multiple antigens in one vaccine unit to evoke strong and long-lasting antibody and cellular responses. The main focus will be a Zika vaccine, with additional preclinical data for a combined Human Papilloma Virus (HPV) and Placental Malaria (PM) vaccine.
The total granted sum for the project is approx. EUR 750,000 and covers a period of 36 months, starting in April 2017.